PCR Stock Overview
Designs, produces, and sells chemical products in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
PCC Rokita SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł71.00 |
| 52 Week High | zł109.80 |
| 52 Week Low | zł68.40 |
| Beta | 1.13 |
| 11 Month Change | -12.45% |
| 3 Month Change | -18.01% |
| 1 Year Change | -20.58% |
| 33 Year Change | -22.99% |
| 5 Year Change | 42.86% |
| Change since IPO | 114.11% |
Recent News & Updates
Recent updates
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?
May 30
Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Shareholder Returns
| PCR | PL Chemicals | PL Market | |
|---|---|---|---|
| 7D | -11.1% | -4.0% | -3.1% |
| 1Y | -20.6% | -15.5% | -1.7% |
Return vs Industry: PCR underperformed the Polish Chemicals industry which returned -15.9% over the past year.
Return vs Market: PCR underperformed the Polish Market which returned -2.4% over the past year.
Price Volatility
| PCR volatility | |
|---|---|
| PCR Average Weekly Movement | 2.2% |
| Chemicals Industry Average Movement | 3.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: PCR has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: PCR's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 917 | Wieslaw Klimkowski | www.pcc.rokita.pl |
PCC Rokita SA designs, produces, and sells chemical products in Poland and internationally. It offers chlorine and alkali; polyurethane insulation systems; household chemicals and cleaning agents; washing preparations; liquid chemicals and disinfectants; vegan body and hair cleansing products; shower gels, hair shampoos, and liquid soaps; foams; and organic products, as well as polyols, naphthalene, and phosphorus derivatives. The company also provides specialty products, including anionic surfactants, alkoxylated fatty alcohols, non-ionic surfactants, synthetic and foam-forming extinguishing agents, synthetic base oils and additives, polyester polyols, chemical raw materials, polyurethane adhesives and prepolymers, polymeric polyols, and polyether polyols.
PCC Rokita SA Fundamentals Summary
| PCR fundamental statistics | |
|---|---|
| Market cap | zł1.41b |
| Earnings (TTM) | zł121.01m |
| Revenue (TTM) | zł2.00b |
11.6x
P/E Ratio0.7x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCR income statement (TTM) | |
|---|---|
| Revenue | zł2.00b |
| Cost of Revenue | zł1.59b |
| Gross Profit | zł404.58m |
| Other Expenses | zł283.57m |
| Earnings | zł121.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.10 |
| Gross Margin | 20.28% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 49.4% |
How did PCR perform over the long term?
See historical performance and comparison